Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

62462 1502285060HCLSReviewMexicoJuly2017.pdf
Energy Boardroom

Amgen's Vectibix scores first-line approval in wild-KRAS colorectal cancer

23.05.2014 / Fierce Pharma

The FDA has OK'd the use of Amgen's Vectibix as a first-line treatment for wild-type KRAS metastatic colorectal cancer. The agency approved the frontline use of the drug in combination with Folfox chemotherapy.

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: